Clinical trials: Unresectable Stage III NSCLC
Non-Small Cell Lung Cancer
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic…
- Trial name
- SKYSCRAPER-01 (NCT04294810)
- Testing
- Atezolizumab, Tiragolumab
- Where
- 134 sites in United States, Australia and 21 more
- Volunteers
- 620 people
- Sponsor
- Hoffmann-La Roche
NSCLC Stage III, SHR-1701
SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer
This randomized phase II exploratory clinical study aims to evaluate the efficacy and safety of SHR-1701 in patients with unresectable stage III non-small cell lung cancer (NSCLC).
- Conditions
- NSCLC Stage III, SHR-1701, Chemoradiotherapy
- Trial name
- NCT07619911
- Testing
- SHR-1701 combined with platinum-doublet chemotherapy induction therapy, SHR-1701 consolidation therapy, Platinum-doublet chemotherapy
- Volunteers
- 84 people
- Sponsor
- Fudan University
Adult Solid Tumor, Breast Cancer
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. St. John's wort may interfere with the effectiveness of chemotherapy.
- Conditions
- Adult Solid Tumor, Breast Cancer, Head and Neck Cancer, Kidney and Urinary Cancer
- Trial name
- NCT00041171
- Testing
- Hypericum perforatum, docetaxel
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Small Cell Lung Cancer
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee…
- Trial name
- HORIZON 1 (NCT05170204)
- Testing
- Alectinib, Entrectinib, Durvalumab
- Where
- 45 sites in United States, Australia and 17 more
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.
- Trial name
- NCT00191139
- Testing
- gemcitabine, docetaxel, cisplatin
- Where
- 15 sites in United States, Argentina and 2 more
- Volunteers
- 64 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
The investigators will obtain a cohort of patients from multiple large cancer centers in China and try to unravel the efficacy of "radiotherapy combined with EGFR-TKI", which may provide some evidences for the treatment of stage…
- Conditions
- Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer, EGFR Mutation-Related Tumors
- Trial name
- NCT04304638
- Testing
- radiation or chemo-radiation, EGFR-TKI Inhibitor
- Volunteers
- 450 people
- Sponsor
- Chinese Academy of Medical Sciences
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 following concurrent chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer.
- Trial name
- PACIFIC (NCT02125461)
- Testing
- MEDI4736
- Where
- 236 sites in United States, Australia and 24 more
- Volunteers
- 713 people
- Sponsor
- AstraZeneca
NSCLC, Stage III
Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
The purpose of this conversion therapy study is to evaluate the safety and efficacy of neoadjuvant of Tislelizumab combined with platinum doublet for stage III unresectable locally advanced NSCLC.
- Trial name
- NCT05611879
- Testing
- Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC), Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Non Small Cell Lung Cancer (Stage III)
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
- Trial name
- LAURA (NCT03521154)
- Testing
- Osimertinib 80mg/40mg
- Where
- 118 sites in United States, Argentina and 15 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Lung Cancer
Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033553
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 74 sites in United States
- Volunteers
- 69 people
- Sponsor
- Alliance for Clinical Trials in Oncology
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have…
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma
- Trial name
- NCT02595866
- Testing
- Antiretroviral Therapy, Biopsy, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation
Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent…
- Trial name
- NCT02883543
- Testing
- icotinib, Chemotherapy, Radiotherapy
- Volunteers
- 330 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-Small Cell Lung Cancer
Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer
A randomized phase II study to assess the efficacy and safety of Trastuzumab Rezetecan and/or Adebrelimab as consolidation therapy following chemoradiotherapy in patients with unresectable stage III HER2-altered NSCLC.
- Trial name
- NCT07836543
- Testing
- Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab, Trastuzumab Rezetecan (SHR-A1811), Adebrelimab
- Volunteers
- 105 people
- Sponsor
- Ming Chen
Stage III Non-small-cell Lung Cancer
Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.
About 20-30% of patients with stage III non-small cell lung cancer (NSCLC) are unresectable and definitive concurrent radiochemotherapy is the standard care.
- Trial name
- NCT05331833
- Testing
- The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.
- Volunteers
- 90 people
- Sponsor
- Jianguo Sun
Neoadjuvant Non-Small Cell Lung Cancer
Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
The project is a Phase III, randomized, open-label, multicenter study in which approximately 36 patients with unresectable Stage III ALK positive Lung Adenocarcinoma will be randomized 1:1 to receive lorlatinib or…
- Trial name
- NCT06858410
- Testing
- lorlatinib, concurrent/sequential platinum-based chemoradiotherapy
- Volunteers
- 36 people
- Sponsor
- Guangdong Association of Clinical Trials
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent RT and maintenance osimertinib in chemotherapy ineligible or refusal adult patients with Stage III…
- Trial name
- NSCLC (NCT07295821)
- Testing
- Osimertinib
- Where
- 20 sites in China
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Unresectable Stage III NSCLC
Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.
A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.
- Trial name
- ON TRAX (NCT04381494)
- Testing
- Multiparametric Mobile Technology
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Stage III NSCLC
Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)
This is a multi-center, open-label, randomized Phase 2 trial evaluating PDR001 in two arms for concurrent chemoradiation and consolidation in the treatment-naïve patients with locally advanced, unresectable stage III NSCLC.
- Trial name
- NCT03945227
- Testing
- standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001, PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001
- Where
- South Korea
- Sponsor
- Yonsei University